Clinical and treatment characteristics
| Low-dose rate | High-dose rate | P value | 95% CI | |
| Total | 284 (68%) | 136 (32%) | ||
| Median follow-up, months | 22 | 11 | ||
| Range | 1–132 | 1–41 | ||
| Age, years | 0.22 | −2.817 to 2.262 | ||
| Mean±SD | 56.1±12 | 56.4±13.2 | ||
| Median (range) | 55 (22–93) | 56(26–86) | ||
| FIGO stage | 0.001 | 0.000 to 0.007 | ||
| IB1 | 8 (2.8%) | 6 (4.4%) | ||
| IB2 | 15 (5.3%) | 15 (11%) | ||
| IIA | 33 (11.6%) | 9 (6.6%) | ||
| IIA1 | 1 (0.4%) | 0 (0%) | ||
| IIA2 | 1 (0.4%) | 1 (0.7%) | ||
| IIB | 131 (46.1%) | 37 (27.2%) | ||
| IIIA | 17 (6%) | 6 (4.4%) | ||
| IIIB | 78 (27.5%) | 62 (45.6%) | ||
| Tumor size (cm) | 0.42 | −1.76 to 1.88 | ||
| <4 | 30 (10.6%) | 18 (13.2%) | ||
| >4 | 254 (89.4%) | 118 (86.8%) | ||
| Median | 5 (2–8) | 5 (1–10) | ||
| Chemotherapy cycles | 0.19 | −1.051 to 1.1713 | ||
| <5 weeks | 102 (34.9%) | 40 (29.4%) | ||
| At least 5 weeks | 182 (64.1%) | 96 (70.6%) | ||
| Histology | 0.16 | 0.149 to 0.223 | ||
| Squamous cell | 264 (93%) | 122 (89.7%) | ||
| Adenocarcinoma | 19 (6.7%) | 11 (8.1%) | ||
| Others | 1 (0.4%) | 3 (2.2%) | ||
| Radiation dose (EQD2), mean±SD | ||||
| Total point A dose | 80.4±8.4 | 81.4±8.4 | ||
| Point B dose contribution from brachytherapy only | 8.5±2 | 8.9±1.9 | ||
| Total point B dose | 57.8±4.7 | 58.2±5.7 |
EQD2, equivalent dose at 2 Gy.